{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}],"title":"Complete Response"},{"measurements":[{"groupId":"OG000","value":"14"}],"title":"Partial Response"},{"measurements":[{"groupId":"OG000","value":"12"}],"title":"No CR or PR"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"as assessed by overall response rates after three months of treatment in patients with relapsed or refractory HCL. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR","groups":[{"description":"Eligible patients will receive vemurafenib at a dose of 960mg orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days).","id":"OG000","title":"Vemurafenib"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"3 months","title":"Efficacy of Vemurafenib","type":"PRIMARY","unitOfMeasure":"Participants"}